Brought to you by 
Schwarz licenses US rights to Nastech scopolamine gel
30 Mar 2001
Executive Summary
Schwarz Pharma Inc. (US affiliate of Schwarz Pharma AG) licensed US marketing rights to Nastech's Phase II/III intranasal scopolamine gel for motion sickness. An NDA is expected to be filed in the first quarter of 1998.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schwarz licenses US rights to Nastech scopolamine gel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice